Nofinity Logo

Latest Analyses(7)

KitchenAid Artisan Grinder Review: Is It Really Good Enough for Espresso?
2 min read

KitchenAid Artisan Grinder Review: Is It Really Good Enough for Espresso?

KitchenAid Artisan Grinder Review: Is It Really Good Enough for Espresso?

The KitchenAid Artisan grinder was tested as a budget-friendly option for filter coffee and espresso. The team is positively surprised – it delivers a solid espresso for the price (around €150 / $160).

Design and Operation

  • Timer-based: Dosing is controlled by an adjustable grind time.
  • Conical burrs with 70 grind settings, where 1 is coarsest and 70 is finest (reverse of usual).
  • Mostly plastic, lightweight (2.9 kg / 6.4 lbs), and compact (38 cm / 15 in tall, 22 cm / 8.7 in deep).
  • Convenient portafilter holder fits common models (e.g., De'Longhi Dedica, KitchenAid 58 mm).

Espresso Quality

  • Fine enough for espresso: Tested at setting 64 out of 70.
  • Result: Sweet, smooth, creamy espresso with pleasant texture – very good for the price.
  • Particle distribution (measured with ZHAW): Main peak at 317 microns, fine particle content at 36% – solid for medium to dark roasts.

Speed and Temperature

  • Grind time: 13.4 seconds for 18 g – solid mid-range.
  • Temperature rises after repeated grinds: After 5 shots, grounds reach 38°C (about 10°C above room temperature). A break after 5 cycles is recommended.

Retention and Consistency

  • Temporary retention: 3.2 g (old coffee remains for next grind).
  • Total retention: 3.4 g (0.2 g permanent).
  • High dose accuracy: Deviation of only ±0.1 g over 5 grinds.

Other Features

  • Quiet: 77 decibels.
  • Low static: Coffee falls cleanly into the portafilter.
  • Not for light, complex roasts, but ideal for dark, heavy blends.
  • Easy bean swap: Inner burr can be removed.

Bottom Line

The KitchenAid Artisan is a strong performer at around €150/$160. It's perfect for beginners or as a companion to cheaper espresso machines. For single-dosing enthusiasts, alternatives start around €250/$270, but it's recommendable in its price class.

Mushrooms for the Mind & Immune System | Paul Stamets
4 min read

Mushrooms for the Mind & Immune System | Paul Stamets

The Mycelial Network: Earth's Natural Intelligence
  • Paul Stamets introduces mycelium as the immune system and neural network of the forest. A single cubic inch of soil can contain 1 to 8 miles of these fungal networks, setting up the microbiome and enabling ecosystems to thrive.
  • He emphasizes the "entourage effect" — the synergy of hundreds of molecules in whole fungi makes them more effective than isolated pharmaceutical compounds.
Fortifying the Immune System: The Agarikon & Turkey Tail Clinical Trials
  • Detailed results from clinical trials using a mycelial extract of Agarikon and Turkey Tail:
    • Reduced vaccine side effects: Drastically lowered headaches, muscle aches, coughing, and sneezing after mRNA vaccines (key vectors of transmission).
    • Enhanced antibody persistence: A 3x higher antibody count 6 months post-vaccination compared to the placebo group, despite only 4 days of supplementation.
    • Faster recovery: Unvaccinated individuals with COVID recovered 5.1 days sooner than the placebo group (more effective than Tamiflu). The extract decouples reactogenicity from immunogenicity.
  • Stark warning: H5N1 (Bird Flu) has jumped to 90 mammal species with a 40-50% fatality rate in humans. Stamets argues elevating innate immunity is our best defense.
The Psychedelic Revolution: Therapeutics, Neuroplasticity & The Tryptamine Universe
  • Set, Setting, and Integration are critical: Stamets turned down his own father for a session because the mother wasn't participating. Therapy and community support are non-negotiable for safe outcomes.
  • Dosing Protocols:
    • Micro-dosing: Sub-perceptual (~0.1g) for mood, depression, and anxiety relief.
    • Museum dose: A low sensory dose (~0.5g) for enhanced appreciation (art, music).
    • Heroic dose: High doses (5g+), often a single lifetime session for profound trauma resolution.
  • The Stamets Stack: The combination of Psilocybin + Lion's Mane + Niacin. A Nature study showed a 50% increase in finger-tapping speed, indicating powerful neuroplasticity and psychomotor benefits.
  • The Tryptamine Universe: The discovery of tryptophan (the precursor to psilocybin and serotonin) on the Bennu asteroid by NASA leads Stamets to a profound conclusion: the universe is filled with the molecules of consciousness and happiness.
Brain Health & Longevity: Lion's Mane, Cordyceps & Push-ups
  • Lion's Mane: Proven to stimulate NGF (Nerve Growth Factor) and BDNF, promoting neurogenesis. Effects are cumulative over weeks.
  • Cordyceps: Supports cellular energy (ATP) and oxygen utilization (VO2 max), acting as a natural performance adaptogen.
  • Mycoremediation: Highly effective for hydrocarbons (oil spills), but largely impractical for dioxins and plastics in complex ecosystems (the mycelium prefers more nutritious food).
  • Paul's Longevity Protocol:
    • Daily push-ups. He cites a Harvard study showing men who can do 40 push-ups in a single set have a 97% reduced risk of cardiac arrest.
    • Daily supplementation with Agarikon and Turkey Tail to maintain baseline immune readiness, especially before travel or high-exposure events.
Conclusion: A Call for Biological Wisdom
  • Stamets urges the integration of natural intelligence with artificial intelligence. He believes leveraging the complexity of fungi is key to solving our greatest challenges in immunity, mental health, and ecology, advocating for a legacy of creativity and collaboration.
FIS, GPN, International Paper, IP, SW, PKG, Bunge, BG and more – S&P 500 419 to 396...
3 min read

FIS, GPN, International Paper, IP, SW, PKG, Bunge, BG and more – S&P 500 419 to 396...

S&P 500 Stock Analysis Summary

This video analyzes S&P 500 stocks, focusing on the bottom 100 companies. The speaker highlights that while the market is expensive, opportunities exist in negatively valued sectors. Key insights include:

General Market Assessment

  • The S&P 500 is the priciest market globally, but some stocks are cheap due to negative sentiment, e.g., in housing or SpaceX-related companies.
  • Expected total return for the bottom 100 stocks is around 6% (e.g., Domino's Pizza).
  • Charter Communications offers high upside but high risk.
  • The speaker prefers Amazon over similar companies like Textron.

Main Analysis: Fidelity National (FIS)

  • Business Model: Payment processor with 1 billion cards and 30% of the U.S. economy.
  • Issues: Declining revenue growth, flat margins, stagnant free cash flow. The company cut guidance and lost its CFO.
  • Valuation: Price-to-earnings ratio (P/E) of 4, dividend yield 6%. The stock is cheap but risky due to negative outlook.
  • Conclusion: Interesting for long-term investors, but with high volatility. The speaker added FIS to his portfolio.

Global Payments Network (GPN)

  • Failed Takeover: Due to financing issues and debt of $45 billion.
  • Valuation: Fair value according to Michael Burry between $45 and $60. At $90, a takeover is uneconomical.
  • Opportunities: If the company manages its $18 billion debt, the stock could rise.

Paper and Packaging Companies

  • International Paper, Smurfit, Packaging Corporation of America (PKG): Cyclical businesses with recurring ups and downs.
  • PKG: Best value with high returns on capital. International Paper and Smurfit are less attractive.
  • Recommendation: The sector is difficult for long-term investors; better suited for short-term cycles.

Bunge (BG)

  • Business Model: Food processing. Lower quality than ADM.
  • Valuation: P/E of 10, dividend yield 2.8%. Cheap during cyclical downturns, but the speaker waits for a yield of at least 5%.
  • Conclusion: Monitoring as part of ADM engagement.

Other Companies

  • APA Corporation: Dependent on oil prices. Only interesting if oil falls below $60.
  • General Mills: Dividend yield 7%, but declining sales (real minus 7%). Possible takeover, but risky.
  • Best Buy: Booms on good news, but high volatility.
  • Equifax: Affected by housing market, but cheap.
  • Nordson, DuPont, CF Industries: All fairly valued or cyclical; not particularly attractive.

Strategy

  • The speaker prioritizes stable dividends and long-term compounding.
  • He recommends using negative sentiment as an opportunity, but accepting risks.
  • Further details on Genuine Parts (GPC) and Mosaic are linked in the video description.
Democrats Are Back. Is Crypto in Trouble?
2 min read

Democrats Are Back. Is Crypto in Trouble?

Political Outlook for Crypto (2026)

Analyst Justin Slaughter assesses the current situation for the crypto industry in the US as mixed. After a positive period under Trump and Republicans, two more difficult years with the returned Democrats are ahead.

Core Theses:

  • No Targeted Annihilation: Democrats will not target crypto exclusively but scrutinize it as part of a broader agenda against corporations and technology (Big Tech, AI).
  • Broad Agenda, Limited Teeth: The focus is on many areas (from Nvidia to Trump-linked firms). However, the concrete enforcement power of Congress is limited without controlling the regulatory agencies (SEC, CFTC).
  • Main Conflict within Democrats: The struggle is not just about Trump, but about the party's fundamental direction – between 'pragmatic regulation' and an 'economic populist' course (represented by Elizabeth Warren).
  • The Fight over 2008: Many Democratic finance policymakers fear a new financial crisis. They see crypto as a replay of the deregulation of swaps, potentially leading to harsh regulation.

Opportunities and Risks:

  • Opportunity: The crypto industry has proven the value of the 'crypto voter' (17-point swing to Republicans). A renewed war on crypto could drive this voter back.
  • Risk: Democratic leadership (e.g., Warren) denies the existence of the crypto voter and seeks a final attack.
  • Time as an Ally: Younger, less biased lawmakers (under 45) understand crypto better. The industry must build bridges, present new use cases (e.g., Hyperliquid for 24/7 trading), and move on from the Biden era's past.

Recommendations:

  • Let the past rest: Stop arguing about the Biden administration's mistakes.
  • Focus on the essentials: Explain concrete use cases (faster, cheaper payments, dollar dominance) in the language of Democrats.
  • Diversity of voices: Engage more crypto advocates with diverse political backgrounds in the dialogue.
Conclusion

The next two years will be tougher for crypto, but not existential. The outcome depends on the Democrats' internal party struggle and the industry's ability to present itself as a mature, solution-oriented technology.

Bitcoin & Krypto Crash - Wie tief kann es noch gehen? HIER kaufe ich!
2 min read

Bitcoin & Krypto Crash - Wie tief kann es noch gehen? HIER kaufe ich!

📉 Bitcoin & Crypto Crash – Analysis and Outlook

Current Market Situation
  • Bitcoin is just below $65,000 and has lost its weekly EMA/SMA.
  • Strong sell-off over the weekend, altcoins particularly affected.
  • Greed & Fear Index at 10 (extreme fear).
Possible Reasons for the Sell-off
  • Binance rumors: Speculation about insolvency, but CEO CZ denied sales. Still, caution advised – exchange not regulated.
  • Coinbase sales: Data shows selling pressure from Coinbase Prime (–$1 billion).
  • ETF outflows and thin order books amplify volatility.
  • Macro: High interest rates, political uncertainty, Microsoft outage (little crypto relevance).
On-Chain Data: Bottom Indicators
  • Short-Term Holder MVRV/SOP: Value Zone at $52,000 – $60,000 – historically a good buying zone.
  • Bitcoin mining cost: around $61,800 – below that, mining becomes unprofitable, potentially increasing sell pressure.
  • Wallet losses: Over $8 billion for short-term holders – record level.
Personal Strategy of the YouTuber
  • Open orders at $60,000 / $57,000 / $55,000 / $53,000 / $50,000 (increasing sizes).
  • Still 25–30% cash – plans to buy another 20%.
  • Long-term horizon (5–10 years), no leveraged products.
  • Recommendation: Use regulated exchanges (e.g., Bitvavo for savings plan, OKX for active trading).
Altcoin Market: Caution Advised
  • Many altcoins like Astar show pump-and-dump patterns.
  • The YouTuber advises against active trading – altcoins are only for short-term trading, not holding.
  • Own altcoin portfolio down 35% – still only one-third of planned amount invested.
Important Events This Week
  • Nvidia earnings (Tuesday) – possible price movement, CEO return of Jensen Huang discussed.
  • Trump-Putin meeting – geopolitical tensions.
  • FED speech (Kevin Wash) – little impact expected.
  • IPO of 'Tropic' – six times oversubscribed, but risk of hype dump.
Conclusion & Outlook
  • Short-term sideways with downward tendency, support at $57,000 critical.
  • If 57k breaks, $50,000 threatens.
  • Nevertheless: Shopping time for long-term buys – but only with cash, not leverage.
  • YouTube channel offers portfolio challenge and Discord channel for real-time updates.
Russian Honeypot: I Was Trained To Control A Man's Mind With Sex! | John Kiriakou & Aliia Roza
3 min read

Russian Honeypot: I Was Trained To Control A Man's Mind With Sex! | John Kiriakou & Aliia Roza

In this episode, former CIA officer John Kiriakou and former Russian honeypot agent Aliia Roza discuss the recent affair between Nvidia CEO Jensen Huang and an alleged Chinese spy, Alice Wong. They reveal the methods of sex espionage and how such operations are orchestrated.

The Jensen Huang Case
  • Honeypot Operation: Alice Wong, a supposed TV anchor, was used as bait to seduce Huang and smuggle $5 billion worth of Nvidia chips to China.
  • Poor Cover: Her company Megaspeed was a front with no real employees – a sign of sloppy tradecraft.
  • Political Fallout: President Trump allegedly ignored warnings about the relationship, raising national security concerns.
Aliia Roza's Honeypot Experience
  • Recruitment: At age 18, her father, an intelligence officer, forced her into a Russian espionage program aimed at controlling men through psychological manipulation and sex.
  • Training Techniques:
    • Love Bombing: Overwhelming praise for the target's achievements.
    • Social Engineering: Creating a staged reality to ensnare the target.
    • Anchoring: Before meeting the target, she would masturbate while looking at his photo, using a keyword and scent as anchors to link sexual arousal to him.
  • Betrayal: Her own commander exposed her as a mole, leading to a near-fatal attack by criminals. The crime lord she had seduced saved her life but was later killed.
Psychological Manipulation Techniques
  • Information Control: Analyzing the target's inner circle to infiltrate his life.
  • Emotional Dependency: Creating a soulmate illusion so the target feels complete only with the agent.
  • Isolation: Slowly alienating the target from family and friends by planting doubts.
  • Gaslighting: Repeatedly questioning the target's reality to make him doubt himself and become easier to control.
Key Insights
  • Espionage is ubiquitous: An estimated 10,000 to 15,000 foreign intelligence officers operate in Washington D.C. alone.
  • Lack of Empathy: Both John and Aliia display sociopathic traits – they can read people perfectly but struggle to form genuine emotional bonds.
  • Guilt and Redemption: Aliia carries guilt from deaths caused by her missions. Today, she uses her knowledge to teach women how to avoid manipulation.
Conclusion

The episode uncovers the dark side of espionage and how sex is weaponized. Aliia Roza's book Honey Trap and John Kiriakou's works provide deeper insights into this shadowy world.

416 ‒ The science of mitochondria: their role in health, aging, disease, and much more
6 min read

416 ‒ The science of mitochondria: their role in health, aging, disease, and much more

Mitochondria: More Than Just Powerhouses of the Cell

In this episode of the Drive podcast, Dr. Peter Attia speaks with renowned scientist Dr. Navdeep Chandel about the complex world of mitochondria. The conversation demystifies the hype around this organelle, delving into its three core functions:

  • Traditional View: ATP Production and Anabolism: Mitochondria are the primary producers of ATP (the cell's energy currency) and also supply building blocks (metabolites) for lipids, nucleotides, and proteins.
  • Revolutionary New Function 1: Communication via Signals: Mitochondria actively send signals to the cell, for example, in the form of hydrogen peroxide (H₂O₂) . Once dismissed as harmful, low doses of H₂O₂ are now recognized as an important signal for immune function and cell differentiation. Metabolites like alpha-ketoglutarate even control epigenetics (e.g., DNA demethylation).
  • Revolutionary New Function 2: Immune Response and Cell Death: Mitochondrial DNA or RNA can activate the immune system, similar to foreign pathogens. Furthermore, the release of cytochrome c from the mitochondrion is the central signal for programmed cell death (apoptosis).
Mitochondrial Dysfunction: A Paradox?

Contrary to popular belief, Dr. Chandel is skeptical that declining ATP production is the primary cause of normal aging. Three crucial points:

  • Large Reserve Capacity: More than 70% of mitochondrial function must be lost before symptoms appear – similar to a car that, despite a lower top speed, is still fully functional in city traffic.
  • Mutation Studies: Mouse models with massively increased mitochondrial DNA mutations (10-fold above normal) do not show a typical aging phenotype. Aging seems to stem more from miscommunication (signal problems) rather than a lack of energy or building materials.
  • Measurability: The only good, albeit rough, test is maximal oxygen uptake (VO₂max) under stress (e.g., cycle ergometry). From Dr. Chandel's perspective, blood, urine, or breath tests are not valid as they only provide a snapshot (steady state) and not actual functional capacity (flux).
Metformin: A Renaissance Drug with a Focus on the Gut

Metformin, an old diabetes drug, is discussed as a potential "geroprotector." Dr. Chandel presents new research findings:

  • Mechanism of Action: Metformin inhibits Complex I of the respiratory chain. In the gut, this leads to increased glucose uptake, which lowers blood sugar levels – an important health effect.
  • The Gut as a Key Organ: Metformin's effectiveness depends critically on organic cation transporters that bring it into the cell. Dr. Chandel shows that the primary site of action is not the liver but the gut. There, it inhibits mitochondrial function, leading to positive effects on blood sugar, gut microbiome, and inflammation markers (reducing IL-6).
  • Potential in Cancer: In tumors possessing the necessary transporter, metformin could work by inhibiting cell growth (anabolism). This mechanism might also suppress the formation of clonal hematopoiesis (CHIP) , a risk factor for cardiovascular disease.
  • Practice for Healthy Individuals: Dr. Chandel considers taking metformin himself, primarily for its anti-inflammatory effects, e.g., against air pollution. He recommends taking it 30 minutes before a meal and advises supplementation with Vitamin B12 and possibly citrulline (e.g., from watermelon) to prevent potential deficiencies. He warns against using the expensive and unregulated berberine instead, as it acts very similarly.
Supplement Jungle: Where is the Evidence?

Dr. Chandel critically examines many touted "mitochondrial boosters" against his three principles: 1. Where does it go? 2. What is its molecular target? 3. Does it work in humans?

  • Urolithin A: Is barely detectable in the body and is rapidly metabolized. It has no clear target. Data is too thin for a general recommendation.
  • Alpha-Ketoglutarate: Has a clear target (epigenetics) and promising but yet-to-be-completed human studies. More of a niche candidate.
  • NAD Precursors (NR, NMN): NAD levels decline with age, but whether it becomes limiting is unclear. Human studies (e.g., ITP) were negative. More suitable for specific applications (e.g., liver regeneration).
  • CoQ10, L-Carnitine, Citrulline: Levels are sufficient in a normal, healthy diet. CoQ10 can be beneficial during statin therapy, but the evidence is inconsistent.
  • Methylene Blue & Red Light Therapy: Both have potential targets in Complex IV (cytochrome c oxidase), but clinical evidence is weak. Red light therapy shows significant effects for skin rejuvenation and, surprisingly, for lowering blood sugar (through improved glucose uptake). Hyperbaric oxygen therapy is not considered beneficial for general health.
Conclusion & Outlook

Dr. Chandel advocates for a new way of thinking: Instead of viewing mitochondria only as ATP suppliers, we must understand their signaling functions. The biggest challenge is the lack of fundamental funding for metabolism research compared to genomics. A "moonshot for metabolism" could yield groundbreaking therapies for aging, cancer, and inflammation. Metformin currently appears to be the most promising and best-studied "geroprotective" agent among the substances discussed.

Note: This podcast is for general information only and does not replace medical advice. For health-related questions, please consult your physician.